谁能从服用药物中受益,以及什么时候? 关于从根本上重组我们对心血管疾病的初级预防的思考
1Departments of Epidemiology and Cardiology, Erasmus MC-University Medical Center Rotterdam, The Netherlands. Department of Clinical Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA.
No abstract available in PubMed .
更多相关视频
04:30A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease V: Interprofessional Care
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
